Global MET TKIs Market Growth 2024-2030

Publication ID:

LPI11242608

Publication Date:

November 19, 2024

Pages:

130

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

MET tyrosine kinase inhibitors (TKIs) are targeted therapies designed to block the activity of the MET receptor tyrosine kinase.These inhibitors, including drugs like crizotinib, capmatinib, and tepotinib, are used to treat cancers with MET alterations, such as non-small cell lung cancer (NSCLC) and gastric cancer.
The global MET TKIs market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
The 鈥淢ET TKIs Industry Forecast鈥� looks at past sales and reviews total world MET TKIs sales in 2023, providing a comprehensive analysis by region and market sector of projected MET TKIs sales for 2024 through 2030. With MET TKIs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world MET TKIs industry.
This Insight Report provides a comprehensive analysis of the global MET TKIs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on MET TKIs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global MET TKIs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for MET TKIs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global MET TKIs.
United States market for MET TKIs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for MET TKIs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for MET TKIs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key MET TKIs players cover Pfizer, Novartis, Merck, Exelixis, Haihe Biopharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of MET TKIs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Multi-target Inhibitors
Single-target Inhibitors
Segmentation by Application:
Non-small Cell Lung Cancer
Medullary Thyroid Cancer
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Pfizer
Novartis
Merck
Exelixis
Haihe Biopharma
CSPC Pharmaceutical
WuXi STA
Shanghai Hutchison Pharmaceuticals
Avistone Pharmaceuticals Biotechnology
Asymchem
Wanbang Biopharmaceuticals
Drug International
Genvio Pharma
Everest Pharmaceuticals
Beacom
Teva
Cipla
BDR Pharma
Zydus
Key Questions Addressed in this Report
What is the 10-year outlook for the global MET TKIs market?
What factors are driving MET TKIs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do MET TKIs market opportunities vary by end market size?
How does MET TKIs break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global MET TKIs Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for MET TKIs by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for MET TKIs by Country/Region, 2019, 2023 & 2030
2.2 MET TKIs Segment by Type
2.2.1 Multi-target Inhibitors
2.2.2 Single-target Inhibitors
2.3 MET TKIs Sales by Type
2.3.1 Global MET TKIs Sales Market Share by Type (2019-2024)
2.3.2 Global MET TKIs Revenue and Market Share by Type (2019-2024)
2.3.3 Global MET TKIs Sale Price by Type (2019-2024)
2.4 MET TKIs Segment by Application
2.4.1 Non-small Cell Lung Cancer
2.4.2 Medullary Thyroid Cancer
2.4.3 Other
2.5 MET TKIs Sales by Application
2.5.1 Global MET TKIs Sale Market Share by Application (2019-2024)
2.5.2 Global MET TKIs Revenue and Market Share by Application (2019-2024)
2.5.3 Global MET TKIs Sale Price by Application (2019-2024)
3 Global by Company
3.1 Global MET TKIs Breakdown Data by Company
3.1.1 Global MET TKIs Annual Sales by Company (2019-2024)
3.1.2 Global MET TKIs Sales Market Share by Company (2019-2024)
3.2 Global MET TKIs Annual Revenue by Company (2019-2024)
3.2.1 Global MET TKIs Revenue by Company (2019-2024)
3.2.2 Global MET TKIs Revenue Market Share by Company (2019-2024)
3.3 Global MET TKIs Sale Price by Company
3.4 Key Manufacturers MET TKIs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers MET TKIs Product Location Distribution
3.4.2 Players MET TKIs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for MET TKIs by Geographic Region
4.1 World Historic MET TKIs Market Size by Geographic Region (2019-2024)
4.1.1 Global MET TKIs Annual Sales by Geographic Region (2019-2024)
4.1.2 Global MET TKIs Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic MET TKIs Market Size by Country/Region (2019-2024)
4.2.1 Global MET TKIs Annual Sales by Country/Region (2019-2024)
4.2.2 Global MET TKIs Annual Revenue by Country/Region (2019-2024)
4.3 Americas MET TKIs Sales Growth
4.4 APAC MET TKIs Sales Growth
4.5 Europe MET TKIs Sales Growth
4.6 Middle East & Africa MET TKIs Sales Growth
5 Americas
5.1 Americas MET TKIs Sales by Country
5.1.1 Americas MET TKIs Sales by Country (2019-2024)
5.1.2 Americas MET TKIs Revenue by Country (2019-2024)
5.2 Americas MET TKIs Sales by Type (2019-2024)
5.3 Americas MET TKIs Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC MET TKIs Sales by Region
6.1.1 APAC MET TKIs Sales by Region (2019-2024)
6.1.2 APAC MET TKIs Revenue by Region (2019-2024)
6.2 APAC MET TKIs Sales by Type (2019-2024)
6.3 APAC MET TKIs Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe MET TKIs by Country
7.1.1 Europe MET TKIs Sales by Country (2019-2024)
7.1.2 Europe MET TKIs Revenue by Country (2019-2024)
7.2 Europe MET TKIs Sales by Type (2019-2024)
7.3 Europe MET TKIs Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa MET TKIs by Country
8.1.1 Middle East & Africa MET TKIs Sales by Country (2019-2024)
8.1.2 Middle East & Africa MET TKIs Revenue by Country (2019-2024)
8.2 Middle East & Africa MET TKIs Sales by Type (2019-2024)
8.3 Middle East & Africa MET TKIs Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of MET TKIs
10.3 Manufacturing Process Analysis of MET TKIs
10.4 Industry Chain Structure of MET TKIs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 MET TKIs Distributors
11.3 MET TKIs Customer
12 World Forecast Review for MET TKIs by Geographic Region
12.1 Global MET TKIs Market Size Forecast by Region
12.1.1 Global MET TKIs Forecast by Region (2025-2030)
12.1.2 Global MET TKIs Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global MET TKIs Forecast by Type (2025-2030)
12.7 Global MET TKIs Forecast by Application (2025-2030)
13 Key Players Analysis
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer MET TKIs Product Portfolios and Specifications
13.1.3 Pfizer MET TKIs Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Novartis
13.2.1 Novartis Company Information
13.2.2 Novartis MET TKIs Product Portfolios and Specifications
13.2.3 Novartis MET TKIs Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Novartis Main Business Overview
13.2.5 Novartis Latest Developments
13.3 Merck
13.3.1 Merck Company Information
13.3.2 Merck MET TKIs Product Portfolios and Specifications
13.3.3 Merck MET TKIs Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Merck Main Business Overview
13.3.5 Merck Latest Developments
13.4 Exelixis
13.4.1 Exelixis Company Information
13.4.2 Exelixis MET TKIs Product Portfolios and Specifications
13.4.3 Exelixis MET TKIs Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Exelixis Main Business Overview
13.4.5 Exelixis Latest Developments
13.5 Haihe Biopharma
13.5.1 Haihe Biopharma Company Information
13.5.2 Haihe Biopharma MET TKIs Product Portfolios and Specifications
13.5.3 Haihe Biopharma MET TKIs Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Haihe Biopharma Main Business Overview
13.5.5 Haihe Biopharma Latest Developments
13.6 CSPC Pharmaceutical
13.6.1 CSPC Pharmaceutical Company Information
13.6.2 CSPC Pharmaceutical MET TKIs Product Portfolios and Specifications
13.6.3 CSPC Pharmaceutical MET TKIs Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 CSPC Pharmaceutical Main Business Overview
13.6.5 CSPC Pharmaceutical Latest Developments
13.7 WuXi STA
13.7.1 WuXi STA Company Information
13.7.2 WuXi STA MET TKIs Product Portfolios and Specifications
13.7.3 WuXi STA MET TKIs Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 WuXi STA Main Business Overview
13.7.5 WuXi STA Latest Developments
13.8 Shanghai Hutchison Pharmaceuticals
13.8.1 Shanghai Hutchison Pharmaceuticals Company Information
13.8.2 Shanghai Hutchison Pharmaceuticals MET TKIs Product Portfolios and Specifications
13.8.3 Shanghai Hutchison Pharmaceuticals MET TKIs Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Shanghai Hutchison Pharmaceuticals Main Business Overview
13.8.5 Shanghai Hutchison Pharmaceuticals Latest Developments
13.9 Avistone Pharmaceuticals Biotechnology
13.9.1 Avistone Pharmaceuticals Biotechnology Company Information
13.9.2 Avistone Pharmaceuticals Biotechnology MET TKIs Product Portfolios and Specifications
13.9.3 Avistone Pharmaceuticals Biotechnology MET TKIs Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Avistone Pharmaceuticals Biotechnology Main Business Overview
13.9.5 Avistone Pharmaceuticals Biotechnology Latest Developments
13.10 Asymchem
13.10.1 Asymchem Company Information
13.10.2 Asymchem MET TKIs Product Portfolios and Specifications
13.10.3 Asymchem MET TKIs Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Asymchem Main Business Overview
13.10.5 Asymchem Latest Developments
13.11 Wanbang Biopharmaceuticals
13.11.1 Wanbang Biopharmaceuticals Company Information
13.11.2 Wanbang Biopharmaceuticals MET TKIs Product Portfolios and Specifications
13.11.3 Wanbang Biopharmaceuticals MET TKIs Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Wanbang Biopharmaceuticals Main Business Overview
13.11.5 Wanbang Biopharmaceuticals Latest Developments
13.12 Drug International
13.12.1 Drug International Company Information
13.12.2 Drug International MET TKIs Product Portfolios and Specifications
13.12.3 Drug International MET TKIs Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Drug International Main Business Overview
13.12.5 Drug International Latest Developments
13.13 Genvio Pharma
13.13.1 Genvio Pharma Company Information
13.13.2 Genvio Pharma MET TKIs Product Portfolios and Specifications
13.13.3 Genvio Pharma MET TKIs Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Genvio Pharma Main Business Overview
13.13.5 Genvio Pharma Latest Developments
13.14 Everest Pharmaceuticals
13.14.1 Everest Pharmaceuticals Company Information
13.14.2 Everest Pharmaceuticals MET TKIs Product Portfolios and Specifications
13.14.3 Everest Pharmaceuticals MET TKIs Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Everest Pharmaceuticals Main Business Overview
13.14.5 Everest Pharmaceuticals Latest Developments
13.15 Beacom
13.15.1 Beacom Company Information
13.15.2 Beacom MET TKIs Product Portfolios and Specifications
13.15.3 Beacom MET TKIs Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 Beacom Main Business Overview
13.15.5 Beacom Latest Developments
13.16 Teva
13.16.1 Teva Company Information
13.16.2 Teva MET TKIs Product Portfolios and Specifications
13.16.3 Teva MET TKIs Sales, Revenue, Price and Gross Margin (2019-2024)
13.16.4 Teva Main Business Overview
13.16.5 Teva Latest Developments
13.17 Cipla
13.17.1 Cipla Company Information
13.17.2 Cipla MET TKIs Product Portfolios and Specifications
13.17.3 Cipla MET TKIs Sales, Revenue, Price and Gross Margin (2019-2024)
13.17.4 Cipla Main Business Overview
13.17.5 Cipla Latest Developments
13.18 BDR Pharma
13.18.1 BDR Pharma Company Information
13.18.2 BDR Pharma MET TKIs Product Portfolios and Specifications
13.18.3 BDR Pharma MET TKIs Sales, Revenue, Price and Gross Margin (2019-2024)
13.18.4 BDR Pharma Main Business Overview
13.18.5 BDR Pharma Latest Developments
13.19 Zydus
13.19.1 Zydus Company Information
13.19.2 Zydus MET TKIs Product Portfolios and Specifications
13.19.3 Zydus MET TKIs Sales, Revenue, Price and Gross Margin (2019-2024)
13.19.4 Zydus Main Business Overview
13.19.5 Zydus Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂